Clinical trials depend on access to the right data, systems, and applications at the right time. Yet clinical trial data access is consistently treated as an IT support activity rather than an essential part of how clinical trial teams work. A study team member joins a trial. They need access to several applications, study data
The oncology pipeline has never been more promising, or more operationally demanding. Across the life sciences industry, precision medicine, antibody-drug conjugates (ADCs), cell and gene therapies, and biomarker-driven research are reshaping how oncology programs are developed. Clinical teams are designing more targeted studies, working with increasingly specialized patient populations, and incorporating new sources of evidence
Consider this scenario. A clinical study is underway. Enrollment is progressing, sites are active, and dashboards suggest things are broadly on track. Now imagine being able to ask a simple question midway through the study: Which sites are likely to miss their enrollment targets over the next few weeks? Or, are there any early signals
Why Faster Clinical Trials Need More Than Automation: The Role of AI in Clinical Execution Read more
Pharma R&D is entering a new phase of acceleration. As development pipelines expand and submission volumes increase, organizations are placing greater focus on the operational infrastructure needed to support submission readiness, compliance management, and global regulatory coordination at scale. But while scientific innovation has evolved rapidly, many submission and compliance processes still depend on fragmented
In most pharma and biotech organizations, delays in clinical trials, regulatory submissions, and overall drug development timelines are rarely surprising. They tend to show up across different stages of the lifecycle, often in ways that feel routine. For example, during the study start-up phase, timelines slip because site documents are still under review. Later, a
The True Cost of Delays in Clinical and Regulatory Operations – and How to Reduce It Read more
There’s a point in every drug development program where progress slows, not because the science is incomplete, but because coordination becomes the constraint. By the time a regulatory submission is assembled, the underlying work is largely done. Data has been generated, trials completed, and evidence validated. Yet moving from submission readiness to approval often depends
How AI-Powered Process Automation is Compressing Regulatory Timelines in Drug Development Read more
Picture this: A critical clinical trial is weeks from a milestone when temperature-sensitive investigational drugs sit in Singapore customs for three days. Meanwhile, a site coordinator in Boston can’t locate their latest shipment, and your team has just spent two hours manually reconciling inventory across five different spreadsheets. These scenarios aren’t rare. They’re the everyday
Solving Clinical Supply Chain Challenges with Process Automation Read more
What is Study Start-Up in Clinical Trials? Study Start-Up (SSU) is the phase in clinical trials where everything is prepared before a site can begin enrolling patients. It includes activities such as finalizing essential study documents, completing regulatory and ethics approvals, collecting required site information, and activating sites for trial execution. In simple terms, Study
Agentic AI in Study Start-Up: Automating Documents, Approvals, and Site Activation Read more
If you work in pharma or biotech, you know that accurate, complete, and well-coordinated regulatory submissions are critical to keeping development timelines on track. Every filing — whether it’s a new drug application, a variation, or a label update — passes through multiple hands across clinical, CMC, safety, and regulatory teams. And while the science
How Modern Teams Ace Regulatory Submissions: From Fragmentation to Flow Read more
Picture this: A global medical device manufacturer misses a small but crucial update to its product labeling in Europe. The result? A product recall, millions lost, and significant damage to trust. Or consider a pharma company where a single error in batch release documentation delays a life-saving drug’s approval. These are not rare occurrences. They
How Process Automation and AI Minimize Human Error in the Drug Development Lifecycle Read more